{"id":475893,"date":"2021-04-14T06:21:04","date_gmt":"2021-04-14T10:21:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-confirms-substantial-pre-orders-for-its-25mg-cbd-cbg-infused-tauri-gum\/"},"modified":"2021-04-14T06:21:04","modified_gmt":"2021-04-14T10:21:04","slug":"tauriga-sciences-inc-confirms-substantial-pre-orders-for-its-25mg-cbd-cbg-infused-tauri-gum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-confirms-substantial-pre-orders-for-its-25mg-cbd-cbg-infused-tauri-gum\/","title":{"rendered":"Tauriga Sciences Inc. Confirms Substantial Pre-Orders for its 25mg CBD & CBG Infused Tauri-Gum"},"content":{"rendered":"
\n

NEW YORK, NY, April 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire<\/u><\/a> — Tauriga Sciences, Inc. (OTCQB:\u00a0TAUG) (\u201cTauriga\u201d or the \u201cCompany\u201d), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has received substantial Pre-Orders for its new, 25mg CBD & CBG infused Tauri-Gum\u2122 versions.\u00a0 The enhanced 25mg CBD & CBG infusion concentrations apply to five distinct Tauri-Gum\u2122 SKUs: Mint (CBD), Blood Orange (CBD), Pomegranate (CBD), Peach-Lemon (CBG), and Black Currant (CBG).<\/p>\n

CBD = CANNABIDIOL<\/p>\n

CBG = CANNABIGEROL<\/p>\n

The Company has made the following strategic decision:\u00a0There will be No Increase in Tauri-Gum\u2122 Retail Prices (\u201cMSRP\u201d)<\/em><\/strong>.\u00a0\u00a0The Company has been successful in reducing costs (basic factors of production costs), pursuant to the Tauri-Gum\u2122 manufacturing process.<\/p>\n

Lastly, the Company has generated strong E-Commerce sales during the first two weeks of April 2021.\u00a0 Between the Pre-Orders (25mg Tauri-Gum\u2122) and its strong E-Commerce sales, the Company is confident in its growth prospects for Fiscal Year 2022 (Period: April 1, 2021 \u2013 March 31, 2022).<\/p>\n

\n ABOUT TAURIGA SCIENCES INC.<\/strong>\n <\/p>\n

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.\u00a0\u00a0The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (\u201cCBD\u201d) and Cannabigerol (\u201cCBG\u201d) Edibles market segment.\u00a0\u00a0The main product line, branded as Tauri-Gum\u2122, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum\u2122 Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum\u2122 Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum\u2122 Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum\u2122 Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum\u2122 Flavor: Golden Raspberry).\u00a0\u00a0The Company\u2019s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website:\u00a0www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at\u00a0http:\/\/www.tauriga.com<\/u><\/a><\/p>\n

Complementary to the Company\u2019s retail business, is its ongoing Pharmaceutical Development initiative.\u00a0 This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum\u2122, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.\u00a0\u00a0The Patent, filed with the U.S.P.T.O. is Titled \u201cMEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT\u201d.\u00a0 On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.<\/p>\n

The Company is headquartered in Wappingers Falls, New York.\u00a0\u00a0In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.<\/p>\n

\n DISCLAIMER — Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains certain \u201cforward-looking statements\u201d as defined by the Private Securities Litigation Reform Act of 1995 which represent management\u2019s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpects,\u201d \u201canticipates,\u201d believes, \u201chopes,\u201d \u201cbelieves,\u201d or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management\u2019s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in\u00a0 forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the \u201cRisk Factors\u201d section of Tauriga\u2019s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email:\u00a0 sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram:\u00a0 @sethsms47
Twitter: @SethMShaw
Corp. Website:\u00a0\u00a0 www.tauriga.com<\/u><\/a>
E-Commerce Website:\u00a0 www.taurigum.com<\/u><\/a><\/p>\n

\n Attachment<\/strong>\n <\/p>\n